Supernus Pharmaceuticals (SUPN) Amortization - Intangibles (2019 - 2025)

Supernus Pharmaceuticals (SUPN) has 7 years of Amortization - Intangibles data on file, last reported at $24.6 million in Q4 2025.

• On a quarterly basis, Amortization - Intangibles rose 34.6% year-over-year to $24.6 million in Q4 2025; TTM through Dec 2025 was $89.5 million, a 14.78% increase from a year earlier, with the FY2025 full-year figure at $89.5 million, up 14.72% from the prior year.
• Amortization - Intangibles for Q4 2025 stood at $24.6 million, up from $24.3 million in the prior quarter.
• Over the last five years, Amortization - Intangibles for SUPN reached as high as $24.6 million in Q4 2025 and fell as low as $5.9 million in Q2 2021.
• Historically, Amortization - Intangibles has averaged $18.1 million across 5 years, with a median of $20.1 million in 2023.
• Across the five-year window, Amortization - Intangibles surged 375.81% in 2021 and dropped 13.47% in 2024, its largest moves.
• Year by year, Amortization - Intangibles stood at $12.0 million in 2021, then surged by 72.39% to $20.7 million in 2022, then increased by 1.71% to $21.1 million in 2023, then fell by 13.47% to $18.2 million in 2024, then surged by 34.6% to $24.6 million in 2025.
• Per Business Quant data, the three most recent Amortization - Intangibles figures were $24.6 million in Q4 2025, $24.3 million in Q3 2025, and $20.8 million in Q2 2025.